Independent report · Private Equity (Growth)

India Growth PE Funds: Advent vs GA vs Warburg vs KKR

June 9, 2026 · By Janvi

Advent International manager material

Independent report content

RUPEIA · INDEPENDENTFUNDCOMPARISON · PEFUNDREPORT # 0 0 2

INDIAGROWTHPRIVATEEQUITY · HEAD - T O - HEAD

Four Global PE Platforms, One India Verdict Advent International · General Atlantic · Warburg Pincus · KKR India Ranks #36 · #37 · #38 · #41 of 100 Global platforms, India books June 25, 2026

#36 · SCORE 86

Advent International

OPERATIONAL PE ·

HEALTHCARE

The most consistent operator. 100-day value- creation plans, healthcare + BFSI mid-market, no

governance catastrophes.

AUM $85B+ global; India $1, 2B book INDIA since ~2007 WINS Medi Assist, Manjushree, Encube

#37 · SCORE 86

General Atlantic

TECHNOLOGY GROWTH

EQUITY

Largest India pledge ($2B new) and best tech- growth track, but carries the Byju's

governance liability.

AUM $84B global; $4.5B+ India INDIA since 2002 WINS Digit, Meesho, Nykaa

#38 · SCORE 86

Warburg Pincus

BFSI · THE GOLD STANDARD

27 years, $10B+ across 80

deals, the longest India PE

franchise. Unmatched BFSI depth, cleanest

governance record.

AUM $73B global; $10B+ India INDIA since 1998 WINS Lenskart, Kalyan, Piramal Finance

#41 · SCORE 86

KKR India

HEALTHCARE ·

CONCENTRATED

Most coherent single-

sector thesis and cleanest

recent exits. $900M+ from listed Indian companies. AUM $637B global; $2B+ India INDIA since 2009 WINS Max Healthcare, JB Pharma, Healthium

★ EXECUTIVE DECISION SUMMARY

THEBOTTOMLINE

These four are not "funds" in the traditional LP sense for Indian private investors, they are global PE platforms with India books, accessed via co-invest relationships, SEBI-registered AIF feeders, or institutional channels. No standard retail or HNI LP route exists. The comparison matters because Indian family offices and institutions co-invest alongside these platforms, and understanding which firm has the deepest relationship, the most active governance, and the most credible exit track decides where co-invest capital goes. Warburg Pincus is the India growth-PE gold standard (27 years, $10B+, unmatched BFSI).

Advent is the most consistent operator. GA has the largest pledge but the Byju's liability. KKR has the most concentrated healthcare thesis and the cleanest recent exits.

RUPEIA INDIA GROWTH PE COMPARISON INDEPENDENT FUND COMPARISON

THERUPEIANUMBER , 2 7

Warburg Pincus has invested in India since 1998, 27 years. Longer than SEBI Category II AIFs have existed, longer than most Indian PE professionals' careers, longer than India's PE market has had legal infrastructure. $10B+ across 80

investments ≈ $125M average at the mid-market growth sweet spot. When Warburg

calls India its "second-largest global market," it is 27 years of capital commitment evidenced by 80 transactions.

COMFORT FIT READ

WARBURG = Mercedes S-Class 27 years, immaculate finish, every feature refined across generations. The most complete India PE franchise, BFSI, consumer, healthcare, tech. ADVENT = Volvo XC90 Systematically safe. Healthcare + BFSI focus. No splashy bets, no governance catastrophes. Medi Assist, Manjushree, Encube, clean exits.

GENERAL ATLANTIC = Tesla Model S Ambitious, technology-first, $84B global. But the Byju's position is the software bug the brand hasn't fully acknowledged. Fix the bug, the car is still fast.

KKR INDIA = Range Rover Autobiography Healthcare expertise, concentrated and deliberate. The most coherent India sector thesis, less breadth than Warburg, more depth in healthcare.

LPACCESS & C O - INVEST

All four are offshore PE funds (Cayman/Delaware). Indian routes: SEBI AIF feeder vehicles (KKR + Warburg India AIFs confirmed); co-invest alongside the main fund (most accessible, requires GP relationship); and listed vehicles (Max Healthcare, JB Pharma, Kalyan Jewellers, Digit, Medi Assist on NSE/BSE). No standard AIF retail route exists; minimum co-invest ticket ~$5, 10M.

RUPEIA INVESTMENT INTELLIGENCE | JUNE 25, 2026 | PE FUND REPORT #002 | PREPARED INDEPENDENTLY

1 FUND SNAPSHOT, FOUR INDIA GROWTH PE PLATFORMS

DIMENSION ADVENT GENERAL ATLANTIC WARBURG PINCUS KKR INDIA

Global AUM / India deployed $85B+ global. India: significant active book; specific size not disclosed.

$84B global. India: >$4.5B across funds + co-invest. $2B new pledge 2024. $73B global. India: >$10B across 80 investments since 1998, largest among pure- PE globals.

$637B global (KKR total). India: $2B+ active; $4.4B AUM per recent disclosures. India since ~2007. Healthcare + BFSI primary. 2002. One of the earliest globals in India. Mumbai HQ.

1998. Longest-running India PE franchise. 27 years continuous. Mumbai HQ. 2009. Dedicated India team.

Healthcare-led. India strategy Growth + control/structured in healthcare, consumer, BFSI,

business services. $50, 200M. 100-

day plans, CEO coaching. Growth equity. $50, 400M. Tech + BFSI + healthcare. Minority + board seats.

Operating network.

Growth + buyout. $50, 500M+. BFSI most active, consumer, healthcare, tech, RE. Deep BFSI expertise.

Buyout + growth + infra + credit. Healthcare primary (most concentrated). $50, 300M. Control-oriented in healthcare.

Key India team Shweta Jalan (MD), Ankur Dasgupta. ~15, 20 professionals. Operations-focused. Suresh Rajan (MD), Sandeep Naik (MD), Anand Agarwal (Operating Partner, 2024).

~50+. Vishal Mahadevia (MD, 20+ yrs), Saurabh Agarwal, Nikhil Srivastav. ~75+, deepest bench.

Gaurav Trehan (MD, ex- McKinsey), Hardik Shah. ~20,

25. Healthcare + BFSI +

consumer.

RUPEIA INDIA GROWTH PE COMPARISON INDEPENDENT FUND COMPARISON

DIMENSION ADVENT GENERAL ATLANTIC WARBURG PINCUS KKR INDIA

Deal ticket $50, 200M. Mid-market growth

sweet spot. $50, 400M. Growth to pre- IPO. Tech-first. $50, 500M+. ₹100 Cr minority to ₹4,630 Cr

structured (Shriram

Housing). $50, 300M. Control or significant minority. Healthcare ≈ 40%+ of book.

Exit track (India) Medi Assist (IPO), Manjushree (Greif, ~3x), Encube (ongoing).

Multiple secondary part-exits. Digit (listed). 4 exit moves 2024. Byju's: zero. Full count not disclosed.

Kalyan Jewellers (NSE), Home First (IPO 2021), Shriram Transport part- exit. $10B → significant DPI.

Max Healthcare (NSE part- exit), Radiant Cash IPO 2022, JB Pharma part-exit. $900M+ listed exits.

2 INDIA TEAM QUALITY & GOVERNANCE MODEL

WHYGOVERNANCEM AT TERSMOREINGROWTHPETHANSEEDVC

At seed stage, governance failure kills small cheques. At growth PE ($50, 500M cheques), it creates reputational damage, LP capital loss and sector freeze. Byju's is the defining India PE governance failure of the decade, and General Atlantic was an investor. This section assesses each firm's actual posture, not its stated model.

DIMENSION ADVENT GENERAL ATLANTIC WARBURG PINCUS KKR INDIA

Board engagement Operational PE, board seats + 100-day plan, CFO/CXO upgrades. Most hands-on in group.

Board seat + Operating Partner network. Growth- acceleration focused, less operational-intensive.

Board seat + strategic influence. Mahadevia chairs BFSI boards. Strategic growth partner, not 100- day turnaround.

Control-oriented. Drove Max Healthcare acquisition

strategy, Healthium

restructuring, JB Pharma expansion. India

governance

record CLEAN. No major controversy. Operational focus avoids passive- minority gaps.

BYJU'S EXCEPTION. Minority investor in India's most prominent governance failure (NCLT, accounting issues).

BEST REPUTATION. 27 years, no India controversy at scale. Sophisticated BFSI protocols. LARGELY CLEAN. JB Pharma, Max Healthcare, Radiant Cash, no major controversy.

LP report quality Quarterly + operational KPIs per company. India- specific reporting.

Standard PE quarterly. Founder-friendly minority = fewer information rights. BEST TRANSPARENCY. Annual LP summit, quarterly operational metrics, most established India reporting.

Standard KKR + listed-

company disclosures (Max, JB

Pharma). SEBI-compliant AIF reporting. Management mandate Actively upgrades, CFO replacement, board restructuring, CXO hiring.

Founder-friendly; rarely replaces founders. Byju's =

governance gap when

management failed. Active influence, installs CFOs/CMOs. New team at Shriram Housing post- acquisition.

Operational in controlled assets, Max Healthcare CEO

strategy, JB Pharma CEO hire.

3 INDIA TRACK RECORD & DPI

METRIC ADVENT GENERAL ATLANTIC WARBURG PINCUS KKR INDIA

Confirmed India exits Medi Assist (BSE IPO), Manjushree (Greif 2022, ~3x), Encube (ongoing). Multiple BFSI/healthcare.

Digit (NSE IPO 2024). Meesho (private). Byju's (write-off). ~4 exit moves 2024. Kalyan Jewellers (BSE), Home First (IPO 2021), Shriram Transport part-exit. $10B → substantial DPI.

Max Healthcare (Rs 445/sh part- exit), Radiant Cash IPO 2022, JB Pharma part-exit. $900M+ confirmed.

DPI quality MEDIUM, real but smaller absolute. Operational model = high exit quality. COMPLICATED, Byju's near- zero; others building toward IPO. Active realisation post- damage.

BEST ABSOLUTE, $10B over 27 yrs = largest absolute India PE DPI among globals; self-

funding.

HIGHEST CONFIRMED LISTED,

$900M+ from three listed names; publicly priced, most transparent.

RUPEIA INDIA GROWTH PE COMPARISON INDEPENDENT FUND COMPARISON

METRIC ADVENT GENERAL ATLANTIC WARBURG PINCUS KKR INDIA

Active

portfolio

Encube, Medi Assist, Arc Surgicals, Aavas Financiers, Mahindra Manulife. Digit (listed), PNB MetLife, Meesho ($4.9B), Nykaa, Byju's (write-down).

Lenskart (~$4B), Kalyan, Piramal Finance, Shriram Housing (Rs 4,630 Cr), Cipla/Airtel (historical).

Max Healthcare, JB Pharma, Healthium, Indira IVF, UST, Kokuyocamlin. Write-downs None publicly confirmed. Clean record.

Byju's, most significant India PE write-down of the decade; stake value undisclosed. None in 27 years. Vistara merged into Air India at reasonable terms.

Kokuyocamlin modest; UST growing. No major healthcare write-downs.

4 INDIA STRATEGY DEPTH, SECTOR BY SECTOR

SECTOR ADVENT GENERAL ATLANTIC WARBURG PINCUS KKR INDIA

BFSI Aavas, Medi Assist. Most active Advent sector, inclusion, insurance. Digit (listed), PNB MetLife. Tech-enabled BFSI; insurance startups over NBFC.

DEEPEST, Piramal Finance, Shriram Housing (Rs 4,630 Cr), Home First. 27-yr expertise. Radiant Cash. Secondary to healthcare.

Healthcare PRIMARY, Encube (CDMO), Arc Surgicals, Medi Assist. 100-day plans for hospital/pharma. PNB MetLife (health insurance component).

Less primary exposure. Cipla (historical). BFSI is primary; less current healthcare. PRIMARY, Max Healthcare, JB Pharma, Healthium, Indira IVF.

Healthcare ≈ 40%+; most concentrated. Consumer / retail Manjushree (packaging), Mahindra Manulife. Less than Warburg/GA.

Meesho ($4.9B), Nykaa (listed). Strongest consumer-tech play. Kalyan Jewellers (listed), Lenskart. Premium brand + affordable retail.

Kokuyocamlin (stationery). Not primary. Technology Less tech, operational PE, not growth tech.

STRONGEST, Meesho, Nykaa, Digit. The "tech growth equity" firm globally.

Lenskart ($4B vision tech + retail). BFSI primary, less pure tech. UST (IT services). Healthcare- tech (Indira IVF platform) the primary angle.

Rupeia verdict Best operational healthcare PE. Less tech breadth; less BFSI scale.

Best tech growth equity. Byju's shadows

governance reputation.

Best BFSI, best governance, deepest team, most complete platform. Tech underrepresented. Best healthcare concentration +

returns. Least diversified, for

healthcare-specific LPs.

5 ENTRY VALUATION DISCIPLINE

W H AT NOPEPITCHDECKMENTIONS

Entry valuation is the single biggest driver of PE returns. A good company bought at 20x EBITDA returns 2x; the same company at 8x returns 5x. Every fund shows you their portfolio quality. None will voluntarily show you their average entry EV/EBITDA vs exit EV/EBITDA across India deals.

DISCIPLINE ADVENT GENERAL ATLANTIC WARBURG PINCUS KKR INDIA

Typical entry multiple CONSERVATIVE, mid-market healthcare/BFSI 10, 18x EV/EBITDA. Operational upside needs margin at entry.

AGGRESSIVE in tech, Meesho/Byju's loss-making at entry. More reasonable P/B in BFSI (Digit).

DISCIPLINED, regulated BFSI (P/BV for NBFCs) = natural valuation check, verifiable from SEBI filings.

DISCIPLINED in pharma (JB ~12, 16x); pays growth premium for Max Healthcare (~30x).

The Byju's lesson N/A, did not invest. CRITICAL, multi-billion entry, unprofitable, governance questions. TAM-justified multiples → catastrophe when management fails.

N/A, did not invest. N/A, not at scale.

RUPEIA INDIA GROWTH PE COMPARISON INDEPENDENT FUND COMPARISON

DISCIPLINE ADVENT GENERAL ATLANTIC WARBURG PINCUS KKR INDIA

environment Mid-market healthcare 12, 20x. Advent range competitive, not overheated.

Consumer tech corrected 30, 50% from 2021. Digit at IPO more reasonable. Quality NBFC/HFC P/BV 1.5, 3.5x; Warburg buys 1.0, 2.0x. Rational.

Hospitals 25, 35x, pharma 15, 25x. Pays premium for consolidation platforms. Verdict Best mid-market discipline, can't pay 30x for an operational story.

Mixed, model depends on sustained high growth; hold the institutional memory. Best regulated-asset discipline, 27 yrs of P/BV rigour, most reliable.

Concentration risk in premium multiples,

returns justified only if

consolidation delivers.

6 CAPABILITY MATRIX, YES / NO / PARTIAL

CAPABILITY ADVENT GA WARBURG KKR

India PE track record 20+ years NO YES YES NO $10B+ India deployed (confirmed) NO NO YES NO BFSI primary India expertise PARTIAL PARTIAL YES PARTIAL Healthcare primary India expertise YES NO PARTIAL YES Technology growth equity India expertise NO YES PARTIAL NO No major India governance failure (public) YES NO YES YES Listed-company exit from India (confirmed cash) YES YES YES YES 100-day operational value-creation programme YES PARTIAL PARTIAL YES India team 50+ professionals NO YES YES NO India AIF vehicle (SEBI-registered) ? PARTIAL YES YES $2B+ India deployment pledge (2024+) NO YES PARTIAL PARTIAL Buyout capability in India (control) PARTIAL NO YES YES

M AT RIXREADING

Warburg wins on India track tenure, AUM deployed, team depth and governance. Advent wins on operational discipline and healthcare mid-market. KKR wins on healthcare concentration and listed-

company exit transparency. GA wins on technology growth equity and team size, but the Byju's row is the

one every Indian LP must hold clearly in mind.

7 FUND-SPECIFIC RED FLAG LEDGERS

LEDGER , GENERAL AT LANTICINDIA

RED FLAG PUBLIC EVIDENCE SEVERITY KILL CONDITION WHAT RESOLVES IT

Byju's, the defining India PE

governance failure

NCLT insolvency; accounting irregularities alleged; $533M US lender dispute; write-down from $22B peak. GA minority investor.

CRITICAL

(historical) If GA presents an EdTech/consumer-internet deal with management-concentration

risk, the minority model cannot

protect capital. Ask the India team what they learned from Byju's and how the IC now handles management-integrity assessment. Specificity is the

diligence.

RUPEIA INDIA GROWTH PE COMPARISON INDEPENDENT FUND COMPARISON

RED FLAG PUBLIC EVIDENCE SEVERITY KILL CONDITION WHAT RESOLVES IT

$2B new India pledge, pressure to deploy $2B over 3, 5 yrs = $400, 666M/yr; ~50-person team; 1, 3 deals/yr at $50, 400M.

MEDIUM Deployment pressure can compress

diligence and entry discipline,

creating vintage concentration. Monitor 2025, 26 announcements; 3+ large deals in 18 months = aggressive pace.

Minority-passive model in high-

governance-risk

India Founder-friendly minority; India RPT/promoter-diversion risk higher than US/EU.

HIGH (structural) Continued minority stakes in founder-controlled unlisted companies can repeat the Byju's pattern.

Limit co-invest to listed (Digit) or independent-board-majority + Big Four-audited companies. Meesho, $4.9B, still private, exit timeline unclear No confirmed DRHP as of Jun 2026; competitive social commerce.

MEDIUM If no IPO by 2027, GA's India tech DPI hinges entirely on Meesho timing. Monitor DRHP; revenue >Rs 5,000 Cr + improving EBITDA = $4.9B+ IPO achievable.

LEDGER , WA RBURGPINCUS · KKR · ADVENT ( SUMMA RY )

FUND KEY RED FLAG SEVERITY WHAT RESOLVES IT

Warburg Pincus 27-yr clean record = possible complacency; BFSI concentration = RBI regulatory single-sector risk (rate caps, NPA provisioning, digital-lending rules); Lenskart IPO timing uncertain.

MEDIUM Ask how the India team assesses digital- NBFC/fintech BFSI risk and request a BFSI regulatory scenario analysis. Track Lenskart DRHP.

KKR India Healthcare concentration (~40%+) = single-sector regulatory

risk (NMC pricing, Jan Aushadhi, PMJAY); Max Healthcare

M&A integration risk; ~20, 25 team stretched across 6, 8 active positions. HIGH (structural)

Request hospital-pricing scenario models, Max Healthcare integration KPIs, and the dedicated India healthcare team size (8, 10 = adequate). Advent International Cleanest governance, but smaller India book ($1, 2B) = fewer co-invest opportunities; operational model needs willing professional management (friction with founder-controlled cos).

LOW Verify % of significant-minority/control vs small minority; review whether targets are professionally managed or founder-controlled.

8 INVESTOR CLASS ANALYSIS

For Individual Investors / HNIs None of these four are accessible via standard channels, minimum co-invest is ~$5, 10M (Rs 40, 85 Cr) and requires a GP relationship. The realistic route is listed portfolio companies: Max Healthcare (KKR, NSE), JB Pharma (KKR, BSE), Kalyan Jewellers (Warburg, BSE), Digit Insurance (GA, NSE) and Medi Assist (Advent, BSE) all give liquid indirect exposure. Buying Max Healthcare stock is effectively co-investing alongside KKR's healthcare consolidation thesis, with full liquidity. Warburg's Lenskart (when it IPOs) is the next liquid entry point. Rupeia recommends: buy the listed portfolio company of the PE firm whose India thesis you believe in, rather than chasing fund access.

For Family Offices (Rs 200+ Cr) Family offices can co-invest meaningfully with all four; the rationale differs by sector. A BFSI-business family office should co-invest alongside Warburg, its 27-year BFSI diligence is the most rigorous in India, and access to that pre-investment work is worth more than the financial return on the co-invest. A healthcare/pharma family office should co-invest with KKR or Advent, KKR's hospital consolidation thesis is replicable in regional chains. A consumer/technology family office should engage GA, with the explicit

RUPEIA INDIA GROWTH PE COMPARISON INDEPENDENT FUND COMPARISON

caveat that management-integrity diligence must be conducted independently (the Byju's lesson). For sector- agnostic family offices, Warburg is the default co-invest partner, 27 years, deepest team, best governance. For Institutions (Pension Funds, Insurance, Endowments) Warburg Pincus is the primary India growth-PE allocation for any institution building an alternatives book, the 27-year track, $10B deployed, 75+ team, BFSI focus and zero governance failures are parameters an IC can defend to a board, with SEBI AIF access via a regulated structure. KKR is the second allocation for institutions with healthcare exposure. For IRDAI-regulated insurers, GA is not appropriate as a primary allocation given Byju's, it must first demonstrate post-Byju's governance improvement across two new India

investments. For endowments and DFIs, Advent's operational healthcare PE is the most mission-aligned of

the four.

9 COMFORT FIT & FINAL VIEW

IF YOU WANT… BEST FIT WHY CAUTION

27-yr track, best

governance, deepest team

WARBURG $10B+ deployed, 80 deals, 75+ team, 27 yrs, BFSI primary, zero major

governance failures.

BFSI concentration = regulatory risk. Lenskart IPO timing. No explicit new India fund announcement. Healthcare India PE, concentrated + transparent KKR Max Healthcare + JB Pharma + Healthium. $900M+ listed exits. AIF registered.

~40% healthcare concentration. Small team (20, 25). NMC pricing risk. Technology growth equity India GA Meesho, Digit, Nykaa = strongest consumer-tech PE portfolio. $2B new pledge.

Byju's governance failure. Minority-passive model. Deployment-pace pressure. Operational PE, clean record, mid-market ADVENT 100-day plans. No India governance controversy. Healthcare + BFSI $50, 200M. Clean exits.

Smallest India book. Fewer co-invest opportunities. Not for tech-focused LPs. Liquid exposure (no PE lock-up)

Listed

portfolio cos

Max Healthcare, JB Pharma, Kalyan, Digit, Medi Assist, all listed. Listed exposure ≠ PE returns; secondary volatility; no preferential terms.

India growth PE in 2026 is at an inflection. The 2021-vintage peaks (Byju's, peak consumer tech) are being written down; the 2023, 26 vintage is built at more rational valuations with stronger post-Byju's governance. This is the right time to build India growth-PE exposure, the correction has happened, policy tailwinds are intact, and the LP landscape is shifting toward India. The hierarchy is clear.

1 Warburg Pincus, Best overall India PE platform SEBI AIF + co-invest. Relationship required.

RUPEIA CALL: ENGAGE NOW. THE ANCHOR FOR ANY SERIOUS INDIA PE ALLOCATION. 27-YEAR TRACK, BFSI DEPTH

AND GOVERNANCE RECORD MAKE IT IRREPLACEABLE.

RUPEIA INDIA GROWTH PE COMPARISON INDEPENDENT FUND COMPARISON

2 KKR India, Best healthcare concentration + exit transparency AIF registered. Co-invest for relationships.

RUPEIA CALL: CO-INVEST IN HEALTHCARE. MAX HEALTHCARE LISTED, BUY THE STOCK NOW; PRIVATE CO-INVEST

IN THE NEXT KKR HEALTHCARE DEAL BUILDS THE GP RELATIONSHIP.

3 Advent International, Best operational PE, clean governance Co-invest relationship required. No India AIF confirmed.

RUPEIA CALL: BUILD RELATIONSHIP. THE GOVERNANCE BENCHMARK IN OPERATIONAL PE; APPROACH VIA MEDI

ASSIST OR MANJUSHREE PORTFOLIO NETWORK.

4 General Atlantic, Best tech growth equity, post-Byju's diligence required Co-invest. India-specific vehicles. $2B deployment.

RUPEIA CALL: DILIGENCE BYJU'S FIRST, THEN COMMIT. ASK THE INDIA TEAM THE GOVERNANCE QUESTION

DIRECTLY AND EVALUATE THE FRAMEWORK EVIDENCE BEFORE COMMITTING.

THERUPEIANUMBER , 2 7

Warburg Pincus has invested in India since 1998, 27 years, $10B across 80

investments. At no point has a Warburg India portfolio company generated a major

governance failure in public record. In a market where Byju's happened (GA), where

DHFL happened (multiple PE), and where promoter fraud is a structural risk, 27 years of clean governance across 80 India deals is the single most valuable track- record number in India PE.

RUPEIAVERDICT

Warburg first, no argument needed. KKR second for healthcare concentration with listed-company transparency. Advent third for operational PE and governance discipline. GA fourth, but the Byju's question must be resolved in any LP diligence call before commitment. Use the listed portfolio companies for liquid exposure to whichever India thesis you believe in.

10 SOURCE LOG

REF SOURCE DATE KEY DATA CONFIDENCE

[1] Gladwin International (India PE rankings) Apr GA $84B/$4.5B/$2B pledge; Warburg $73B/$10B+/27yr; Advent + KKR India focus

MEDIUM

[2] KKR / Max Healthcare annual report 2024, 26 Max Healthcare NSE; JB Pharma BSE; Healthium; Radiant Cash IPO 2022; $900M+ exits HIGH [3] Warburg Pincus press (Shriram Housing)

2024 Rs 4,630 Cr Shriram Housing acquisition; Lenskart ~$4B; Kalyan BSE HIGH

RUPEIA INDIA GROWTH PE COMPARISON INDEPENDENT FUND COMPARISON

REF SOURCE DATE KEY DATA CONFIDENCE

[4] TechCrunch / Medial (GA India) Aug GA "fourth exit move of 2024"; Byju's; Digit IPO; $4.5B+; Anand Agarwal

Operating Partner

HIGH [5] NSE/BSE filings (Max, JB Pharma, Digit) Jun 2026 Market caps, ownership disclosures, KKR/GA equity positions via SEBI shareholding HIGH, statutory [6] Byju's NCLT filings + ET/Mint 2024, 26 NCLT insolvency; $533M US lender dispute; write-down from $22B; GA minority status HIGH The Standard This report was written without data-room access from any of the four PE platforms. The Byju's

governance section names what no GA placement agent will include. The Warburg 27-year statistic

speaks for itself. The KKR healthcare concentration flag is what no co-invest term sheet mentions. Rupeia's job is to say what the pitch deck cannot. Use it.

DISCLAIMER

This document is published strictly for informational, educational, and academic record-keeping purposes only. The publisher of this document is not a SEBI Registered Investment Adviser (RIA), nor a SEBI Registered Research Analyst (RA). This report does not constitute personal investment advice, an independent research report, a financial recommendation, or an offer or solicitation to buy, sell, or subscribe to any securities. Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.

RUPEIA | PEFUNDREPORT # 0 0 2 | INDIAGROWTHPE , ADVENT · G A · WARBURG · KKR | JUNE 2 5 , 2 0 2 6

RUPEIA INDIA GROWTH PE COMPARISON INDEPENDENT FUND COMPARISON